Company Overview and News
Nickel market news: Nickel demand in the batteries market is starting to be noticeable. As per Mining News, "electric vehicle demand will double nickel price as soon as 2022."
TNTMF GLCNF AVQ IGO MUM S2R CZI AMSLF POS AUZ HIG RNX PLM.RT REN WNARF MSMGD AXNNF MSMGF WSA RNSGF PSDNF POM AAL IIDDY NMTLF CLQ PLM AAUKF HLPCF WM CSSQF LNZCF NGLOY ARV XTM WSCRF
RENO, Nev., July 10, 2018 (GLOBE NEWSWIRE) -- Pershing Resources Company (OTCPK:PSGR) announced today that it has agreed to acquire ownership interests in two Central Nevada gold-silver mineral properties located in Central Nevada’s active mining districts from Americas Gold Exploration, Inc. (“AGEI”). The West Bolo Project is located within the Hot Creek Range, about twelve miles north of the Tybo Mining District.
PSGR RNSGF REN AUXXF
VANCOUVER, BC / ACCESSWIRE / May 1, 2018 / Renaissance Gold Inc. TSX.V: REN ("RenGold" or the "Company") expects exploration drilling programs on at least seven of its partner-funded projects during 2018. Some of that drilling is ongoing and other programs are planned for later in the year. The following is an update on two of these projects already underway.
AULGF RNSGF KOR REN AU AGG S2R PSPGF CORVF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:REN / Renaissance Gold Inc on message board site Silicon Investor.